These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 26174899)

  • 21. Efficacy and safety of Hizentra(®) in patients with primary immunodeficiency after a dose-equivalent switch from intravenous or subcutaneous replacement therapy.
    Jolles S; Bernatowska E; de Gracia J; Borte M; Cristea V; Peter HH; Belohradsky BH; Wahn V; Neufang-Hüber J; Zenker O; Grimbacher B
    Clin Immunol; 2011 Oct; 141(1):90-102. PubMed ID: 21705277
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Acute myocardial infarction following intravenous immunoglobulin therapy for chronic inflammatory demyelinating polyneuropathy in association with a monoclonal immunoglobulin G paraprotein.
    Stamboulis E; Theodorou V; Kilidireas K; Apostolou T
    Eur Neurol; 2004; 51(1):51. PubMed ID: 14639034
    [No Abstract]   [Full Text] [Related]  

  • 23. Human polyvalent immunoglobulin: new indication. Multifocal motor neuropathy: slightly more muscle strength. Improvement in muscle strength, but frequent hypersensitivity reactions.
    Prescrire Int; 2009 Apr; 18(100):62. PubMed ID: 19585721
    [No Abstract]   [Full Text] [Related]  

  • 24. Recommended timing of routine measles immunization for children who have recently received immune globulin preparations. American Academy of Pediatrics Committee on Infectious Diseases.
    Pediatrics; 1994 Apr; 93(4):682-5. PubMed ID: 8134232
    [No Abstract]   [Full Text] [Related]  

  • 25. Immune globulin intravenous products--notice to hospitals.
    Hogan V
    CMAJ; 1999 Apr; 160(7):1051-2, 1055-6. PubMed ID: 10207352
    [No Abstract]   [Full Text] [Related]  

  • 26. Immune globulin G for treatment of opsoclonus-polymyoclonus syndrome.
    Eirís J; del Rió M; Castro-Gago M
    J Pediatr; 1996 Jul; 129(1):175. PubMed ID: 8757584
    [No Abstract]   [Full Text] [Related]  

  • 27. [Current therapeutic use of gamma globulin preparations].
    Litzman J
    Cas Lek Cesk; 1991 Nov; 130(18-19):556-60. PubMed ID: 1764720
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Multiple necrotic deep wound infections associated with a subcutaneous immunoglobulin infusion.
    Abraham T; Kim YM; Casselman J; Saad A; Wessell KR; Toller-Artis E; Tcheurekdjian H; Hostoffer R
    Ann Allergy Asthma Immunol; 2015 Jul; 115(1):80-2. PubMed ID: 25963449
    [No Abstract]   [Full Text] [Related]  

  • 29. Hemolytic events after the administration of lyophilized versus liquid immune globulin: an analysis of a single manufacturer's safety database.
    Berg R; Jacob D; Fuellenhals E
    Transfusion; 2015 Aug; 55(8):1847-54. PubMed ID: 25867204
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Consensus conference evaluates key issues concerning use of intravenous immune globulin.
    Clin Pharm; 1990 Jul; 9(7):489, 492-3. PubMed ID: 2198122
    [No Abstract]   [Full Text] [Related]  

  • 31. A controlled trial of intravenous immune globulin to reduce nosocomial infections in very-low-birth-weight infants. National Institute of Child Health and Human Development Neonatal Research Network.
    Fanaroff AA; Korones SB; Wright LL; Wright EC; Poland RL; Bauer CB; Tyson JE; Philips JB; Edwards W; Lucey JF
    N Engl J Med; 1994 Apr; 330(16):1107-13. PubMed ID: 8133853
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Use of immune globulin to prevent symptomatic cytomegalovirus disease in transplant recipients--a meta-analysis.
    Glowacki LS; Smaill FM
    Clin Transplant; 1994 Feb; 8(1):10-8. PubMed ID: 8136560
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Availability of immune globulin intravenous for treatment of immune deficient patients--United States, 1997-1998.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 1999 Mar; 48(8):159-62. PubMed ID: 10079062
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Human immunoglobulin and the Guillain-Barre syndrome: new indication. An alternative to plasmapheresis.
    Prescrire Int; 2000 Oct; 9(49):142-3. PubMed ID: 11603414
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Intravenous immune globulin.
    Med Lett Drugs Ther; 1992 Dec; 34(886):116-8. PubMed ID: 1465040
    [No Abstract]   [Full Text] [Related]  

  • 36. Improving utilization of intravenous immune globulin through concurrent use of an indication form.
    Frayha HH; Nuessle SJ; Arishi H; Rayes H; Qunibi WY; Bazarbashi MS
    Eur J Clin Pharmacol; 1997; 52(4):255-60. PubMed ID: 9248761
    [TBL] [Abstract][Full Text] [Related]  

  • 37. ABO-immunoglobulin G antibodies in intravenous immune globulin can interfere in ABO-mismatched kidney transplants.
    Boctor FN; Bhaskaran M; Sheahan B; Heaton WA; Molmenti E
    Transfusion; 2011 Aug; 51(8):1874-5. PubMed ID: 21831188
    [No Abstract]   [Full Text] [Related]  

  • 38. Cost effectiveness of prophylactic intravenous immune globulin in chronic lymphocytic leukemia.
    Weeks JC; Tierney MR; Weinstein MC
    N Engl J Med; 1991 Jul; 325(2):81-6. PubMed ID: 1904989
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Protein-losing enteropathy after the total cavopulmonary connection: impact of intravenous immunoglobulin.
    Zaupper LB; Nielsen BW; Herlin T
    Congenit Heart Dis; 2011; 6(6):624-9. PubMed ID: 22010984
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Intravenous immune globulin in neuromuscular disorders.
    Gupta S
    West J Med; 1997 Nov; 167(5):349-50. PubMed ID: 9392991
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.